Updated:
Moolec Science SA
Moolec Science SA: a public ag-biotech firm using molecular farming to produce animal proteins in plants, targeting food ingredient markets.
Moolec Science SA
Moolec Science SA, founded in 2015, emerged from research at the University of Wisconsin–Madison with a mission to disrupt industrial animal agriculture. The company is structured as a publicly traded entity on the Nasdaq under the ticker MLEC, following a de-SPAC merger in 2024 with a special purpose acquisition company (per SEC filings, 2024). Moolec's core technology platform uses genetic engineering to express animal proteins — such as casein, bovine serum albumin, and collagen — within commodity crops like soybeans, peas, and corn. The company targets the food ingredient market, aiming to supply components for plant-based meat, dairy alternatives, and nutritional products. Its lead product, Piggy Sooy, produces porcine proteins in soybeans. Moolec operates research facilities in the United States and Argentina, with field trials in multiple geographies (per Nasdaq listing documents, 2024). The company employs a small specialized team of scientists and executives. As of its 2024 annual report, Moolec reported fewer than 50 full-time employees (per SEC filing, 2024). It has not disclosed AUM, deployment numbers, or a formal investment portfolio. In 2024, Moolec announced a partnership with a global commodity trader to scale production of its protein-rich soybean varieties (per press release, September 2024). Moolec's structural differentiator is its focus on molecular farming as a capital-light alternative to cultured meat or fermentation — it uses existing agricultural infrastructure rather than building bioreactors. The company's regulatory pathway involves FDA and USDA approvals for genetically engineered crops, a process distinct from that of cell-cultured meat startups. Its public listing provides transparency and liquidity uncommon in early-stage ag-biotech ventures.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Moolec Science SA's core technology?
Moolec's technology is molecular farming — genetically engineering crop plants (soybeans, peas, corn) to produce animal proteins like casein, collagen, and bovine serum albumin. These proteins are harvested from the plants and used as ingredients in plant-based meat, dairy alternatives, and nutritional products. The approach uses standard agricultural farming instead of industrial bioreactors (per SEC filings, 2024).
Is Moolec Science SA a public company?
Yes, Moolec Science SA went public on the Nasdaq in February 2024 via a de-SPAC merger with a special purpose acquisition company. Its ticker is MLEC. The public listing provides financial transparency under SEC reporting requirements (per Nasdaq listing documents, 2024).
Who manages investment decisions at Moolec?
Moolec is an operating company, not an investment firm. Strategic decisions are made by its executive leadership team, including the CEO and founder. The company does not operate a family office or investment vehicle; its capital is deployed into R&D, field trials, and commercialization (per SEC filings, 2024).
What is Piggy Sooy?
Piggy Sooy is Moolec's lead product — a genetically engineered soybean that produces porcine (pig) proteins. The name is a portmanteau of 'piggy' and 'soy.' It is intended as an ingredient for meat alternatives. The product is still at the R&D stage and has not received regulatory approval for commercial sale in the US or EU (per SEC filings, 2024).
How does Moolec Science SA differentiate from cultured meat companies?
Moolec uses molecular farming — growing animal proteins in plants — rather than culturing animal cells in bioreactors. This means it leverages existing agricultural infrastructure (fields, harvesters, processing plants) rather than building high-capital fermentation facilities. The regulatory pathway involves USDA and FDA approval for genetically engineered crops, which is distinct from cell-cultured meat approvals. The approach is intended to be lower cost and more scalable than fermentation-based methods (per company presentations, 2024).
What investment stages does Moolec target?
Moolec is an operating company, not an investment firm. It does not make investments or allocate capital to external funds or startups. Its capital expenditures are directed toward internal R&D, field trials, and scaling production (per SEC filings, 2024).
Where does the underlying wealth for Moolec come from?
Moolec is a publicly traded company with no disclosed family-office or high-net-worth backing in its public filings. Its funding has come from venture capital investors, a de-SPAC transaction, and public markets. No specific family or individual wealth origin is publicly disclosed (per SEC filings, 2024).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: